Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the largest inherited retinal diseases with no FDA-approved therapy

400+ individuals treated to date, with encouraging positive structural and functional clinical findings; and over seven years of long-term tolerability data

Top-line Phase 3 NORTHSTAR data expected in the second half of 2029; Has received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations

Together with IRX-101, this acquisition is expected to expand Tarsus’ presence in retina and further strengthen one of the most compelling pipelines in eye care

Management to host conference call today, August 6, 2026, at 5:00 a.m. PT / 8:00 a.m. ET

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.